Your browser is no longer supported. Please, upgrade your browser.
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own11.80% Shs Outstand40.81M Perf Week-5.66%
Market Cap120.87M Forward P/E- EPS next Y-0.24 Insider Trans-2.52% Shs Float35.41M Perf Month-47.46%
Income-48.30M PEG- EPS next Q-0.01 Inst Own82.50% Short Float7.15% Perf Quarter-60.32%
Sales250.40M P/S0.48 EPS this Y22.30% Inst Trans-7.41% Short Ratio4.19 Perf Half Y-72.22%
Book/sh-0.27 P/B- EPS next Y-145.00% ROA-19.50% Target Price6.40 Perf Year-74.94%
Cash/sh2.17 P/C1.38 EPS next 5Y- ROE-666.10% 52W Range2.98 - 14.14 Perf YTD-70.76%
Dividend- P/FCF- EPS past 5Y27.30% ROI-50.70% 52W High-78.78% Beta0.83
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin74.90% 52W Low0.67% ATR0.37
Employees267 Current Ratio1.20 Sales Q/Q-9.10% Oper. Margin-13.90% RSI (14)28.48 Volatility10.31% 8.78%
OptionableYes Debt/Eq- EPS Q/Q-38.10% Profit Margin-19.30% Rel Volume1.22 Prev Close3.10
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume604.33K Price3.00
Recom3.30 SMA20-23.58% SMA50-43.16% SMA200-63.78% Volume739,542 Change-3.23%
Sep-28-21Upgrade Citigroup Neutral → Buy $11
Jun-25-20Resumed BofA/Merrill Underperform $9
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $75
Sep-17-18Initiated Goldman Sell $42
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Nov-23-21 04:07PM  
Nov-22-21 06:48AM  
Nov-20-21 11:40AM  
Nov-19-21 09:05AM  
Nov-18-21 09:55AM  
Nov-05-21 10:31AM  
Nov-04-21 06:45PM  
Oct-28-21 03:05PM  
Oct-06-21 05:01PM  
Sep-21-21 04:10PM  
Sep-07-21 05:30PM  
Aug-06-21 04:50PM  
Aug-05-21 08:25PM  
Jul-30-21 10:36AM  
Jul-29-21 03:05PM  
Jul-26-21 08:33AM  
Jul-22-21 04:15PM  
Jul-06-21 08:00AM  
Jul-02-21 05:15PM  
Jul-01-21 08:35AM  
Jun-25-21 04:33AM  
Jun-19-21 03:30AM  
Jun-04-21 05:30PM  
May-19-21 05:05PM  
May-07-21 08:52AM  
May-06-21 07:05PM  
May-04-21 05:00PM  
Apr-29-21 05:03PM  
Apr-26-21 09:04AM  
Apr-22-21 04:15PM  
Apr-13-21 05:05PM  
Mar-27-21 11:31AM  
Mar-09-21 05:26AM  
Mar-08-21 05:15PM  
Mar-05-21 01:15AM  
Mar-04-21 04:15PM  
Mar-02-21 04:20PM  
Feb-26-21 10:10AM  
Feb-25-21 04:07PM  
Feb-11-21 04:15PM  
Feb-09-21 04:15PM  
Jan-29-21 08:00AM  
Jan-26-21 04:25AM  
Jan-19-21 09:00AM  
Jan-15-21 08:03AM  
Jan-05-21 04:15PM  
Jan-04-21 04:15PM  
Dec-16-20 05:22PM  
Dec-11-20 05:00PM  
Dec-09-20 07:31PM  
Dec-05-20 11:32AM  
Dec-02-20 08:30AM  
Nov-17-20 04:15PM  
Nov-09-20 12:11PM  
Nov-06-20 04:30PM  
Nov-05-20 05:35PM  
Nov-03-20 04:15PM  
Oct-29-20 12:35PM  
Oct-22-20 04:15PM  
Oct-14-20 05:44PM  
Oct-12-20 12:27PM  
Oct-05-20 04:15PM  
Oct-02-20 05:05PM  
Sep-08-20 04:15PM  
Sep-05-20 11:31AM  
Sep-03-20 05:30PM  
Aug-19-20 04:10PM  
Aug-11-20 02:06PM  
Aug-10-20 05:15PM  
Aug-07-20 01:22PM  
Aug-06-20 06:35PM  
Jul-30-20 12:33PM  
Jul-27-20 08:45AM  
Jul-23-20 04:15PM  
Jul-17-20 07:41AM  
Jul-16-20 04:30PM  
Jul-09-20 05:30PM  
Jul-08-20 07:00PM  
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NOUGUES MAXIMO FChief Financial OfficerNov 02Sale5.6715688567,437Nov 03 06:22 PM
HUNT DOUGLAS MSee RemarksNov 02Sale5.644272,40965,231Nov 03 06:20 PM
AUERBACH ALAN HPRESIDENT AND CEONov 02Sale5.631,79510,1124,414,137Nov 03 06:17 PM
NOUGUES MAXIMO FChief Financial OfficerOct 04Sale6.2016199867,593Oct 06 05:20 PM
HUNT DOUGLAS MSee RemarksOct 04Sale6.154432,72665,658Oct 06 05:15 PM
AUERBACH ALAN HPresident and CEOOct 04Sale6.151,85811,4334,415,932Oct 06 05:04 PM
HUNT DOUGLAS MSee RemarksSep 02Sale7.524223,17466,101Sep 07 03:36 PM
AUERBACH ALAN HPRESIDENT AND CEOSep 02Sale7.601,76413,4034,417,790Sep 03 09:27 PM
NOUGUES MAXIMO FChief Financial OfficerSep 02Sale7.511551,16467,754Sep 03 07:40 PM
NOUGUES MAXIMO FChief Financial OfficerAug 02Sale7.541541,16167,909Aug 03 05:52 PM
HUNT DOUGLAS MSee RemarksAug 02Sale7.534203,16166,523Aug 03 05:49 PM
AUERBACH ALAN HPRESIDENT AND CEOAug 02Sale7.531,76413,2864,419,554Aug 03 05:45 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 02Sale8.845,33247,1214,421,318Jul 06 07:42 PM
NOUGUES MAXIMO FChief Financial OfficerJul 02Sale9.261551,43568,063Jul 06 05:43 PM
HUNT DOUGLAS MSee RemarksJul 02Sale9.151,0169,29866,943Jul 06 05:40 PM
Senderowicz AdrianDirectorJun 11Sale11.1740,993457,7570Jun 15 06:14 PM
MOYES JAY MDirectorJun 10Sale11.3625,248286,8606,322Jun 11 05:36 PM
Miller Ann CalbyDirectorJun 10Sale11.4312,874147,15612,874Jun 11 04:59 PM
WILSON TROY EDWARDDirectorJun 10Sale11.3625,748292,433350Jun 11 07:30 PM
HUNT DOUGLAS MSee RemarksJun 02Sale10.774164,48167,959Jun 04 04:53 PM
AUERBACH ALAN HPRESIDENT AND CEOJun 02Sale10.741,75718,8774,426,650Jun 04 04:49 PM
NOUGUES MAXIMO FChief Financial OfficerMay 03Sale9.911521,50668,370May 05 04:44 PM
HUNT DOUGLAS MSee RemarksMay 03Sale9.914174,13368,375May 05 04:39 PM
AUERBACH ALAN HPRESIDENT AND CEOMay 03Sale9.011,75815,8474,428,407May 05 04:34 PM
NOUGUES MAXIMO FChief Financial OfficerApr 05Sale9.801551,51968,522Apr 06 06:02 PM
HUNT DOUGLAS MSee RemarksApr 05Sale9.804264,17668,792Apr 06 05:58 PM
BRYCE RICHARD PAULSEE REMARKSApr 05Sale9.804264,176121,662Apr 06 05:54 PM
AUERBACH ALAN HPRESIDENT AND CEOApr 05Sale9.801,58415,5284,430,165Apr 06 05:48 PM
NOUGUES MAXIMO FChief Financial OfficerMar 02Sale10.141541,56168,677Mar 04 04:48 PM
HUNT DOUGLAS MSee RemarksMar 02Sale10.164224,28869,218Mar 04 04:43 PM
BRYCE RICHARD PAULSEE REMARKSMar 02Sale10.154224,283122,088Mar 04 04:40 PM
AUERBACH ALAN HPRESIDENT AND CEOMar 02Sale10.141,23812,5564,431,749Mar 04 04:33 PM
NOUGUES MAXIMO FChief Financial OfficerFeb 02Sale12.261792,19513,236Feb 04 05:13 PM
AUERBACH ALAN HPRESIDENT AND CEOFeb 02Sale12.221,22214,9314,283,036Feb 04 05:10 PM
BRYCE RICHARD PAULSEE REMARKSFeb 02Sale12.234155,07669,664Feb 03 07:39 PM
HUNT DOUGLAS MSee RemarksFeb 02Sale12.274125,05449,883Feb 03 06:47 PM
HUNT DOUGLAS MSee RemarksJan 04Sale10.236,46366,14550,295Jan 06 06:42 PM
BRYCE RICHARD PAULSEE REMARKSJan 04Sale10.236,54867,01670,079Jan 06 06:36 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 04Sale10.2218,235186,3804,284,258Jan 06 08:05 PM
NOUGUES MAXIMO FChief Financial OfficerJan 04Sale10.222,14521,93013,415Jan 06 06:48 PM
BRYCE RICHARD PAULSEE REMARKSDec 02Sale11.65921,07276,627Dec 04 04:34 PM
AUERBACH ALAN HPRESIDENT AND CEODec 02Sale11.663554,1384,302,493Dec 04 04:32 PM